Speakers

Prof. Chao-Nan (Miles) Qian

Sun Yat-sen University Cancer Center, China


 

Prof. Francesco Pezzella

John Radcliffe Hospital, University of Oxford, UK


Prof. Raffaella Giavazzi

Mario Negri Institute for Pharmacological Research, Italy


Choice of therapy regimens to accompany antiangiogenic treatments

Raffaella Giavazzi was born in Bergamo, Italy. She is Head of the Laboratory of Biology and Treatment of Metastasis at the Mario Negri Institute for Pharmacological Research (since 1993).
more ... 

Raffaella Giavazzi was born in Bergamo, Italy. She is Head of the Laboratory of Biology and Treatment of Metastasis at the Mario Negri Institute for Pharmacological Research (since 1993).

She obtained her Biological Sciences degree (1979) and her PhD in Pharmacology (1984) at the University of Milan, Italy and the Qualification of Professor in General Pathology and in Applied Biology (2017). She was a post-doc Fellow in the Cancer Metastasis and Treatment Laboratory, NCI-FCRDC, Frederick, MD (1981-‘83), Assistant Professor at the Dept. of Cell Biology of M.D. Anderson Hospital and Tumour Institute, University of Texas in Houston (1983-‘85). She was Honorary Research Fellow and Visiting Professor, Richard Dimble Dept. of Cancer/ICRF, London, UK (1996).

She was adjutant Professor in Oncology at the Medical School of the University of Brescia (2007-‘10) and at the Medical School of the University of Pisa (1999-2010). Since 2012 she is member of the Board of Directors at the University of Trento.

She was consulting scientist for the NCI-Drug Therapeutics Program, USA (1996-2006) and a member of the Executive Committee at the South Europe New Drug Development Organization (1988-2012).

She was in the board (1994-2004) and President (2005-2007) of the Italian Cancer Society, in the board of the European Association for Cancer Research (2008-2012) and of the International Metastasis Research Society (2000-2004). She is member of the American Association for Cancer Research (AACR).

She received the Researcher Career Award “Italian League Against Tumor” (2003) and the “Giorgio Prodi” Lecturship at the Italian Cancer Society (2012).

Raffaella Giavazzi’s research interests are in the field of tumor biology and pharmacology, with a specific interest in the metastatic process and angiogenesis. She is involved in the pre-clinical and clinical development of new therapeutic strategies against cancer.

She has published approximately 200 articles in the field of Cancer Research and communicated approximately 400 studies in national and international congresses.


 

Prof. Robert S. Kerbel

University of Toronto, Canada


Anti-vascular strategies under development to target co-opted tumor blood vessels in metastases

Prof. Robert S. Kerbel received his PhD in immunology in 1972 from the Dept. of Immunology & Microbiology, Queen’s University, Kingston, Ontario, Canada, after which he undertook postdoctoral training in London at the Institute for Cancer Research in tumor immunology.
more ... 
Prof. Robert S. Kerbel received his PhD in immunology in 1972 from the Dept. of Immunology & Microbiology, Queen’s University, Kingston, Ontario, Canada, after which he undertook postdoctoral training in London at the Institute for Cancer Research in tumor immunology. He started his independent research program in 1975 studying tumor immunology and metastasis at Queen's, and was appointed Director of the Cancer Biology Program in the Dept. of Pathology in 1981. In 1985 he was recruited as Director of Cancer Biology Research at Mt. Sinai Hospital, Toronto. He then moved to Sunnybrook Health Sciences Centre to assume the same position from 1991 until 2001. Dr. Kerbel held a Canada Research Chair in Tumor Biology, Angiogenesis & Antiangiogenic Therapy (2001-2015), and is a professor in the Dept. of Medical Biophysics at the University of Toronto, and Senior Scientist at the Sunnybrook Research Institute. His overall main research interest has been devising new cancer treatment strategies having improved efficacy and reduced toxicity for the treatment of metastatic disease. This culminated in his translational studies of combinatorial low-dose ‘metronomic’ chemotherapy with antiangiogenic drugs. Other major contributions include development of improved preclinical investigational therapeutic models in mice involving early stage or advanced metastatic disease, uncovering mechanisms by which antiangiogenic drugs increase chemotherapy efficacy, and elucidating mechanisms of intrinsic or acquired antiangiogenic drug resistance. His current major research interests include assessment of the significance of ‘vessel co-option’ in tumors on response to antiangiogenic drugs, and combination therapy utilizing immune checkpoint inhibitors with VEGF (or ang2) targeting antiangiogenic drugs, using new mouse models for immune therapy his lab is developing. He has published 423 papers, given 874 invited lectures around the world. Among the awards he has received include the 2004 Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology in 2008, a Man of Distinction Honor by the Israel Cancer Research Fund in 2011, and the Colin Thomson Memorial Medal for achievements in cancer research from Worldwide Cancer Research in 2013.


 

Prof. Raymond L. Barnhill

University of Paris Descartes, France

Prof.Raymond L. Barnhill is currently Professor of Pathology at the Institut Curie, and the Faculty of Medicine, University of Paris Descartes, Paris, France. Dr. Barnhill received his MD degree from Duke University and was a postdoctoral fellow and graduate student in the University of Oxford.
more ... 
Prof.Raymond L. Barnhill is currently Professor of Pathology at the Institut Curie, and the Faculty of Medicine, University of Paris Descartes, Paris, France. Dr. Barnhill received his MD degree from Duke University and was a postdoctoral fellow and graduate student in the University of Oxford. He has trained as a dermatologist, anatomic pathologist, and dermatopathologist. His research interests have largely included the biology of melanocytic lesions and melanoma, angiogenesis, mechanisms of metastasis, especially angiotropism and extravascular migratory metastasis with Dr. Claire Lugassy. He has held major academic leadership appointments including Director of Dermatopathology at Brigham and Women’s Hospital and Children’s Hospital, Harvard Medical School, and Director of Dermatopathology (tenured professor) at Johns Hopkins University. Dr. Barnhill has founded both the North American Melanoma Pathology Study Group and in 2007 the International Melanoma Pathology Study Group, of which he is currently President. He has also been an active member of the WHO Melanoma Program, the EORTC Melanoma Group, the AJCC expert panels for melanoma and ophthalmology, and other professional societies. In 2011, he received the Founder’s Award from the American Society of Dermatopathology. Dr. Barnhill is the author of a number of original articles, chapters, and reviews, and the author, co-author, or editor of five books, including three leading textbooks in dermatopathology and the pathology of melanoma.


 

Prof. Baohui Han

Shanghai Chest Hospital, China


Anlotinib as third-line treatment in patients with refractory advanced non-small cell lung cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial

Professor of Dept. of respiratory medicine, Shanghai Chest Hospital; Vice-president of Shanghai Chest Hospital; Chief of Pulmonary Dept. of Shanghai Chest Hospital
more ... 
Professor of Dept. of respiratory medicine, Shanghai Chest Hospital; Vice-president of Shanghai Chest Hospital; Chief of Pulmonary Dept. of Shanghai Chest Hospital; Shanghai City Leading Talent; the State Council special allowance experts; Chief of Clinic trails centre of Shanghai Chest hospital, Shanghai, China
In 1991, Dr. Han received M.D from Zhongshan hospital, Shanghai Medical University, then he gained his PhD from Shanghai Medical University Shanghai, China in 1994. Dr. Han received new technical training in the diagnosis and treatment of lung cancer in MD. Anderson Hospital, Cancer Center in the United States. From July 2000 to September 2001, he was sent to the University of Pittsburgh Medical Center, Cancer institute in the United States as a post doctoral study of tumor immunotherapy for more than 1 years.
Dr. Han specializes in lung cancer biological immune targeted therapy and clinical study of new antitumor drugs. He participated in the international multi-center subject of the IPASS, the EAP, INTEREST, INFORM, S012, MOK-806, CCTC and other dozens of clinical trials, the quantity and quality of its enrolled among the domestic frontier evaluation results in a recent survey of the most influential international multi-center the IPASS clinical research, enrolled patients were number one in China, fourth in the world. He had presided over major academic conferences on lung cancer and has spoken at conferences on lung cancer both at home and abroad. Han is also the recipient of several awards including “ the eighth Chinese respiratory physicians Award ” in 2013 ,“China Medical Science and Technology Award” in 2014, “Shanghai medical science Award” for several times.
Dr. Han has published more than 200 reviewed papers on lung cancer, and he is the editor of ‘tumor biological immune target therapy’ ‘ultrasound bronchoscopy’ ‘anti-tumor angiogenesis therapy ‘etc., edited over 10 monographs.
Dr. Han is a committee member of numerous associations and societies including executive member of CSCO, the chairman of Chinese medical biological immunology society tumor branch, vice president of Shanghai Cancer Society, vice chairman of Shanghai Medical Association of tumor target molecule.


 

Prof. Roy Bicknell

College of Medicine and Dentistry, University of Birmingham, Edgbaston, Birmingham, UK


Multimerin-2, an endothelial matrix protein mediating the endothelial pericyte interaction

Roy Bicknell received his MA and D.Phil from St John's College, University of Oxford in 1984. He was then a NATO post-doctoral fellow at Harvard Medical School working with Professor Bert L Vallee.
more ... 
Roy Bicknell received his MA and D.Phil from St John's College, University of Oxford in 1984. He was then a NATO post-doctoral fellow at Harvard Medical School working with Professor Bert L Vallee. At the time Vallee and Folkman were trying to isolate a putative angiogenic factor and because of his protein expertise he asked Vallee if he could join the team. Angiogenesis was to be his main interest for the next 30 years and remains so today.

In 1989 he moved back to Oxford to set up the Angiogenesis Group of the Imperial Cancer Research Fund in the newly built Institute of Molecular Medicine. His work involved many studies on the newly identified vascular endothelial growth factor (VEGF) as well as other angiogenic factors. With the rise of genomics he became interested in the identification of new endothelial genes. The first was delta-like 4 that was independently identified by three groups. Later came Robo4 that he worked on for several years. Robo4 is the only endothelial specific roundabout gene and was an interesting finding for it showed that all four of the known neuronal guidance pathways have homologues in the endothelial cell involved in angiogenesis. In 2004 he was appointed Professor of Cancer Cell Biology in Oxford.

In 2005 he was recruited to Birmingham and started a five-year Cancer Research UK programme working together with Dr Victoria Heath. They were still interested in novel endothelial genes but focussed on finding those that had potential as targets in tumour vessels. This led to the discovery of C-type lectin 14A (CLEC14A). CLEC14A expression is regulated by shear stress. Low shear stress induces expression and this leads to significantly higher expression in tumour vessels (due to poor blood flow) than in those in healthy tissues. Our work on CLEC14A has taken two paths. The first is to understand its function and the second is to develop it as a target. It is clearly involved in angiogenesis and we recently identified and characterised the interaction with its ligand multimerin-2 (MMRN2). The targeting work is in collaboration with Dr Steve Lee on CAR modified T cells (funded by The Cell Therapy Catapult) and with several companies on antibody drug conjugates. A final interest is in developing vaccines that target the tumour vasculature.


 

Prof. Guoquan Gao

Zhongshan School of Medicine, Sun Yat-Sen University, China


Effects and mechanism of endogenous inhibitors on cancer angiogenesis and lymphangiogenesis.

Prof. Yihai Cao

Karolinska Institute, Sweden


Improving clinical benefits of antiangiogenic cancer therapy

Professor Yihai Cao received his medical training from the Shandong Medical School and his Ph.D. from the Karolinska Institute. He received his postdoctoral training at Dr. Judah Folkman’s laboratory at the Harvard Medical School.
more ... 
Professor Yihai Cao received his medical training from the Shandong Medical School and his Ph.D. from the Karolinska Institute. He received his postdoctoral training at Dr. Judah Folkman’s laboratory at the Harvard Medical School. Cao’s laboratory has focused their interests on studying angiogenesis in tumor growth, metastasis and non-malignant diseases. Through mechanistic studies, he aims to define novel therapeutic targets and resolve clinically unmet demands of antiangiogenic cancer therapy by proposing new concepts and paradigms. Cao´s lab was one of the first describing the role of angiogenesis in controlling adipose tissue functions. His research interests include molecular mechanisms of pathological angiogenesis contributing to obesity, metabolic diseases, diabetic complications, cancer, metastasis, and cardiovascular diseases, with emphasis on clinical relevance and translational research. He received an honorary medical doctor degree (M.D.) from Copenhagen University, Denmark in 2006. He is a guest professor at the Linköping University, Sweden; an honorary professor at the Leicester University, UK; an honorary professor at the Copenhagen University, Denmark; an honorary a professorship at the Shinshu University Japan, and a guest professor at the Beijing University. He received the Fernström research prize in 2004. He also received the Axel Hirsch Prize in medicine 2014. In 2010, Dr. Cao received a distinguished professor award at the Karolinska Institutet. He was ranked as an outstanding scientist by international experts during the Karolinska Institutet quality assessment in 2010. Dr. Cao also received an ERC-advanced research grant award for being the top scientist in Europe. He received a distinguished NOVO Nordisk-advanced grant award. He is a member of European Academy of Sciences and a member of European Academy of Sciences and Arts. His scientific articles have been cited for more than 30 000 times.


 

Prof. Kai Li

Tianjin Medical University, China


Bevacizumab promotes the migration and tube-formation of endothelial cells via up-regulating CD105 expression and activating TGFbeta1 signaling

 

Prof. Shi-Mei Zhuang

Sun Yat-sen University, China


VETC: A novel vascular pattern that promotes metastasis of hepatocellular carcinoma in an EMT-independent manner

Professor Zhuang studied Clinical Medicine (1981-1987) in Shanghai Medical College, Fudan University, P.R. China. Afterwards, she worked as a Pediatrician in Children’s Hospital of Fudan University and received Doctor Degree in Pediatrics (1992).
more ... 
Professor Zhuang studied Clinical Medicine (1981-1987) in Shanghai Medical College, Fudan University, P.R. China. Afterwards, she worked as a Pediatrician in Children’s Hospital of Fudan University and received Doctor Degree in Pediatrics (1992). She was then recruited as a lecturer in State Key Laboratory of Medical Neurobiology, Fudan University. From 1993 to 1994, she was a visiting scholar in Leiden University, The Netherlands. Between 1995 and 1999, she pursued her PhD thesis in the subject of Medical Cell Biology in Linköping University, Sweden. She was then appointed as Assistant Professor in Faculty of Health Sciences, Linköping University in 2000 and as professor in School of Life Sciences, Sun Yat-sen University in 2002.
Dr. Zhuang’s research interest is within the fields of signaling transduction and tumor biology. Her research is now focusing on the regulatory network and clinical significance of non-coding RNA, the mechanisms of HCC development. In recent 10 years, as corresponding author, Dr. Zhuang has produced 34 research articles in peer-reviewed journals, like Lancet Oncol, Hepatology, Cancer Res, with five papers identified as Highly Cited Papers (ESI), two papers as Recommended Articles by F1000, one paper as cover story in Hepatology, and two papers with Editorials in Lancet Oncol and Hepatology.


 

Prof. Bruno Péault

University of Edinburgh, UK


Perivascular cells in tissue scarring, regeneration and malignancy: friends or foes

 

Dr. Manuel Valiente

Brain Metastasis Group at CNIO, Spain


Vascular co-option in brain metastasis: molecular mediators and functional implications

Manuel Valiente (Zaragoza, 1980) has a degree in Veterinary Medicine (1998-2003, Zaragoza) awarded with the Extraordinary Degree Award and the second National Award in Veterinary Medicine.
more ... 
Manuel Valiente (Zaragoza, 1980) has a degree in Veterinary Medicine (1998-2003, Zaragoza) awarded with the Extraordinary Degree Award and the second National Award in Veterinary Medicine.

His interest in the Central Nervous System led him to earn a doctorate in Neuroscience (Instituto de Neurociencias, Alicante, 2005-2009). In the laboratory of Oscar Marín he developed several projects to understand the principles that govern migration of neuronal precursors needed to establish neuronal circuits in the brain. His doctoral work produced seven publications in leading journals in the field (Development, Journal of Neuroscience, Nature) and received the Extraordinary Doctoral Award. To expand his scientific expertise, while maintaining his research within the nervous system, Manuel joined the laboratory of Joan Massagué (MSKCC, New York, 2010-2014). Manuel′s interest focused on finding critical mediators of metastasis specifically required for the initial colonization of metastatic cells in the brain parenchyma. The most significant contributions of this period were the discovery of the molecular basis of high inefficiency during metastatic brain colonization and the identification of a cell adhesion molecule critical for vascular co-option. More recently he has participated in the first proof-of-concept validating experimental therapies against brain related survival mechanisms of metastasis (Nature, 2016), which is now in clinical trials.

Manuel established the Brain Metastasis Group at CNIO in March 2015, where he leads a team of scientists whose goal is to discover critical aspects of the biology of brain metastasis in order to develop new therapeutic opportunities. During this time Manuel has received several awards for his scientific contributions, attracted competitive grants and participated as invited speaker in basic and clinical meetings of brain tumors. His laboratory is interested in finding novel brain metastasis mediators, improve experimental models to incorporate therapies and explore novel methods to target established brain metastasis. All these aims consider the specificity of the brain environment as a critical component to understand the biology of this progression of cancer.


 

Dr.Jackeline Agorreta

Center of Applied Medical Research (CIMA)-University of Navarra, Spain


Effects of targeted therapies and immunotherapy on lung cancer blood vessels

 

Dr Jiangting Hu

Radcliffe Department of Medicine, University of Oxford, UK


Molecular Genomic Approach to the Identification of Predictive Biomarker of Colorectal Cancer in Response to Bevacizumab

Dr Jiangting Hu obtained her bachelor degree in medicine in 1985 and her master degree in public health in 1988 at Shanghai Medical University in Shanghai, China.
more ... 
Dr Jiangting Hu obtained her bachelor degree in medicine in 1985 and her master degree in public health in 1988 at Shanghai Medical University in Shanghai, China. Since 1992, she worked as a research fellow in biological science at University College London, Imperial College, Wellcome Trust Centre for Human Genetics in Oxford. She joined in Professor Francesco Pezzella’s group in 2001 embarking on journey to cancer angiogenesis research using molecular genomic profiling on non-small cell lung cancer. Dr Hu published her influential research article on molecular fingerprints of angiogenic versus non-angiogenic lung cancer in Oncogene in 2005 and awarded DPhil at Wolfson College, University of Oxford in 2006. Dr Hu received merit award for excellent research performance 2006, Nuffield Department of Clinical Laboratory Sciences, University of Oxford. Since then, she has been instrumental in numerous research projects including the role of mitochondrial chaperon TRAP1 in angiogenesis and tumorigenesis; Stratification of early detected lung cancer by molecular profiling; Identification of predictive biomarkers for anti-angiogenesis treatment in colorectal cancer. She also plays a key role in the study of myocardial metabolic and genomic in cardiac hypertrophy. She is now a senior research scientist of Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford.


 

Dr. Claire Lugassy

Institut Curie Research Center, France


 

Dr. Giorgio Seano

Institut Curie Research Center, France


Vessel co-option in glioblastoma: spy it, find the target and shoot

Dr. Giorgio Seano (1982, Turin, Italy) is the Head of the Tumor Microenvironment Lab in Institut Curie Research Center, Orsay-Paris
more ... 
Dr. Giorgio Seano (1982, Turin, Italy) is the Head of the Tumor Microenvironment Lab in Institut Curie Research Center, Orsay-Paris (France). His scientific interests are tumor angiogenesis, vessel co-option, cell migration and radioresistance.
Dr. Seano received his PhD in “Complex Systems in Life Science” in 2010 from University of Turin, Italy. During his PhD training and his first postdoc period in Italy, (a) he investigated tumor angiogenesis and integrins, (b) he provided the first evidence of a new sub-cellular structure – the endothelial podosome rosette – that controls blood vessel branching during sprouting angiogenesis and (c) developed the first ex vivo human knock-down angiogenesis assay.
In 2012, he joined the laboratory of Dr. Rakesh K. Jain in Harvard Medical School (Boston) and focused his research on tumor microenvironment, brain tumors and intravital microscopy. Specifically, he investigated (a) physical forces from brain tumors and their effects on neuro-vascular functions and (b) vessel co-option in glioblastoma.
In 2017, he was selected as a Junior Group Leader in Institut Curie and he is now setting up his new laboratory.
Dr. Seano authored 26 articles, presented 16 seminars on his research, reviewed 15 papers and received 2 prestigious prizes, 2 travel grants and 5 competitive fellowships/grants for his studies.


 

Dr. Steve Yu

Cyagen Biosciences, Cyagen Biosciences, USA


 

Dr. Karl Morten

University of Oxford, UK


The impact of cell culture conditions on potential cancer therapeutics and the hypoxic response

 

Dr. Kabir Khan

University of Toronto, Canada


 

Alia Komsany

Radcliffe Department of Medicine, Oxford University, UK


 

image

  image



image



image



image



image



image



 

  The 4th International Meeting on Cancer and Blood Vessels